Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn’s disease: a multicenter cohort study

• DOI: 10.1186/s12876-022-02304-y
• Publication Date: 2022-05-10T10:02:46Z
• Authors: Nana Tang; Han Chen; Ruidong Chen; Wen Tang; Hongjie Zhang
• Keywords: Erythrocyte sedimentation rate

Abstract Purpose Mucosal healing (MH) has become the treatment goal of patients with Crohn’s disease (CD). This study aims to develop a noninvasive and reliable clinical tool for individual evaluation mucosal in disease. Methods A multicenter retrospective cohort was established. Clinical serological variables were collected. Separate risk factors incorporated into binary logistic regression model. primary model simple established, respectively. The performance evaluated C-index, sensitivity, specificity, positive predictive value (PPV), negative (NPV) accuracy. Internal validation performed small intestinal lesions. Results total 348 consecutive diagnosed CD who underwent endoscopic examination review after from January 2010 June 2021 composed derivation cohort, 112 lesions included cohort. following independently associated MH subsequently prediction model: PLR (platelet lymphocyte ratio), CAR (C-reactive protein albumin ESR (erythrocyte sedimentation rate), HBI (Harvey-Bradshaw Index) score infliximab treatment. only PLR, ESR. better than one C-index (87.5% vs. 83.0%, p = 0.004). There no statistical significance between these two models sensitivity (70.43% 62.61%, 0.467), specificity (87.12% 80.69%, 0.448), PPV (72.97% 61.54%, 0.292), NPV (85.65% 81.39%, 0.614), accuracy (81.61% 74.71%, 0.303). had good calibration high levels explained variation discrimination Conclusions can be used predict post-treatment CD. It also as an indication surveillance evaluate